Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Trichomylin

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aureuspharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 27, 2021


            Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.